Skip to main content
Biosynex logo

Biosynex — Investor Relations & Filings

Ticker · ALBIO ISIN · FR0011005933 LEI · 969500H4BGE1HBLGP566 PA Manufacturing
Open in API
Filings indexed 200 across all filing types
Latest filing 2022-10-12 M&A Activity
Country FR France
Listing PA ALBIO

About Biosynex

https://www.biosynex.com/en/

Biosynex is a company that specializes in the design, manufacture, and distribution of medical diagnostic solutions. Its core product line consists of Rapid Diagnostic Tests (RDTs) for both professional use in clinical settings and for self-testing by the general public. The professional portfolio includes point-of-care (POC) instruments, molecular biology diagnostics (such as PCR tests), and a wide array of immunodiagnostic assays. For the consumer market, Biosynex offers various self-tests and a range of prevention and monitoring devices, including thermometers, blood pressure monitors, and pulse oximeters. The company focuses on providing simple, rapid, and effective tools for screening, diagnosis, and prevention.

Recent filings

Filing Released Lang Actions
BIOSYNEX SA : ACQUISITION DE 100% DES TITRES DE LA START-UP DOC2U ET REALISATION DE L’ACQUISITION DE LA SOCIETE BIGIX PHARMA S.R.L.
M&A Activity Classification · 95% confidence The document text is a press release announcing two completed acquisitions (Doc2U and Bigix Pharma S.R.L.) and details the strategic rationale behind them. It is not a formal regulatory filing like a 10-K or IR. It is an announcement of corporate activity, specifically M&A and strategic development. While it mentions future earnings releases, the primary content is the completion of transactions. This fits best under M&A Activity (TAR) or potentially Regulatory Filings (RNS) if M&A was not an option. Given the explicit focus on 'ACQUISITION' and the completion of a 'programme de développement', TAR (Merger/Takeover Activity) is the most specific fit, although it is a press release announcing the completion rather than the formal tender offer documents. Since TAR covers merger proposals or takeover bids, and this is the finalization of an acquisition, it is the most appropriate category among the specific choices, rather than the general RNS.
2022-10-12 French
BIOSYNEX SA: COMMUNIQUE RELATIF AU PROJET D’OFFRE PUBLIQUE D’ACHAT visant les actions de la société : THERADIAG
M&A Activity Classification · 98% confidence The document is a "COMMUNIQUE RELATIF AU PROJET D'OFFRE PUBLIQUE D'ACHAT" (Press Release relating to the draft Public Purchase Offer) initiated by Biosynex concerning the shares of Theradiag. It explicitly mentions the filing of a "projet de note d'information" (draft information memorandum) with the AMF (Autorité des marchés financiers) under Article 231-16 of the AMF General Regulation. This document details the terms of a tender offer (acquisition of shares) and references the required legal documentation for such an event in the French regulatory context. This clearly falls under the category of a corporate action related to a takeover or acquisition proposal, which corresponds to the M&A Activity (TAR) definition, as it is the announcement and initial documentation related to a takeover bid.
2022-09-23 French
BIOSYNEX SA: DEPOT D’UNE OFFRE PUBLIQUE D’ACHAT VOLONTAIRE SUR LES ACTIONS DE THERADIAG
M&A Activity Classification · 99% confidence The document is titled "DEPOT D'UNE OFFRE PUBLIQUE D'ACHAT VOLONTAIRE SUR LES ACTIONS DE THERADIAG" (Filing of a Voluntary Public Purchase Offer on THERADIAG shares). It explicitly details a takeover bid (OPA) by BIOSYNEX for THERADIAG shares, including the price, premium, and regulatory filing with the AMF (Autorité des marchés financiers). This clearly falls under the category of Merger & Acquisition (M&A) activity, which corresponds to the 'TAR' (Takeover/M&A Activity) filing code.
2022-09-23 French
BIOSYNEX SA: ACQUISITION DE LA SOCIETE BIGIX PHARMA EN ITALIE
M&A Activity Classification · 98% confidence The document announces the acquisition of an Italian company, BIGIX PHARMA S.R.L., by BIOSYNEX. This is a significant corporate action related to mergers and acquisitions (M&A) activity. The text details the target company, the strategic rationale (strengthening the European pharmacy division), and the expected timeline for finalization. This directly aligns with the definition of M&A Activity (TAR). Although it mentions future earnings communication, the primary focus and content are about the takeover/acquisition proposal.
2022-09-22 French
BIOSYNEX SA: CHIFFRE D’AFFAIRES DU 2EME TRIMESTRE IMPACTE PAR LA DECROISSANCE ANNONCEE DE L’ACTIVITE COVID-19
Earnings Release Classification · 95% confidence The document presents summarized financial results for the first half of 2022 (S1 2022), including revenue figures (Chiffre d'affaires) broken down by division and geography, and discusses business progression and outlook. The key indicator is the presentation of period-specific financial data (S1 2022 vs S1 2021) and the explicit mention of the next publication date for the Q3 2022 results. This structure strongly suggests a preliminary announcement of periodic financial results, focusing on key highlights rather than a comprehensive, audited report (like a 10-K) or a full management discussion (MDA). Therefore, it aligns best with the Earnings Release (ER) category, which covers initial announcements of periodical financial results. H2 2022
2022-07-18 French
BIOSYNEX SA: NOUVELLE DATE DE PUBLICATION DU CHIFFRE D’AFFAIRES SEMESTRIEL AU 18 JUILLET 2022
Report Publication Announcement Classification · 99% confidence The document is very short (1786 characters) and its primary purpose is to announce a change in the publication date for the semi-annual revenue figures ('chiffre d'affaires semestriel'). The text explicitly states: 'la publication de son chiffres d'affaires du 1er semestre 2022 est avancée au 18 juillet après Bourse.' This structure—announcing when a report will be released, rather than containing the full report itself—fits the definition of a Report Publication Announcement (RPA). It is not the Interim Report (IR) itself, but the notice about its release timing.
2022-07-12 French

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.